• 1. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 4. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006
• 5. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Introduction to 4,5-Dichloro-2-(trifluoromethyl)quinazoline (CAS No. 1603341-18-9)

4,5-Dichloro-2-(trifluoromethyl)quinazoline, identified by its Chemical Abstracts Service (CAS) number 1603341-18-9, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic aromatic molecule has garnered attention due to its versatile structural framework, which makes it a valuable scaffold for the development of novel bioactive agents. The presence of both chloro and trifluoromethyl substituents enhances its pharmacological potential, enabling interactions with biological targets that are critical for therapeutic intervention.

The quinazoline core is a well-documented motif in drug discovery, with numerous derivatives exhibiting diverse biological activities. In particular, the chloro and trifluoromethyl groups introduce electrophilic centers and modulate lipophilicity, respectively, which are key factors in determining the pharmacokinetic and pharmacodynamic properties of small molecules. This compound exemplifies how strategic functionalization can yield promising candidates for further medicinal chemistry exploration.

Recent advancements in computational chemistry and molecular modeling have facilitated a deeper understanding of the interactions between 4,5-Dichloro-2-(trifluoromethyl)quinazoline and biological targets. Studies suggest that this compound can engage with enzymes and receptors involved in inflammatory pathways, making it a potential lead for the development of anti-inflammatory agents. The trifluoromethyl group, in particular, has been shown to enhance binding affinity and metabolic stability, attributes that are highly desirable in drug design.

Moreover, the dichloro substitution pattern at the 4- and 5-positions introduces reactivity that allows for further derivatization, enabling researchers to fine-tune the pharmacological profile of the molecule. This flexibility has been exploited in several synthetic strategies aimed at generating libraries of quinazoline derivatives for high-throughput screening. Such approaches have accelerated the identification of compounds with enhanced efficacy and reduced toxicity.

In the context of modern drug development, 4,5-Dichloro-2-(trifluoromethyl)quinazoline represents a bridge between academic research and industrial applications. Its synthesis involves well-established organic reactions, including nucleophilic aromatic substitution and Friedel-Crafts alkylation, which ensure scalability and reproducibility. These synthetic pathways have been optimized to minimize side reactions and maximize yield, aligning with green chemistry principles that prioritize sustainability.

The compound's potential extends beyond inflammation; preliminary investigations have explored its activity against microbial pathogens. The quinazoline scaffold is known to disrupt bacterial cell wall synthesis or interfere with essential metabolic processes. By incorporating electron-withdrawing groups such as chloro and trifluoromethyl substituents, researchers aim to improve antimicrobial efficacy while reducing resistance development.

From a regulatory perspective, 4,5-Dichloro-2-(trifluoromethyl)quinazoline (CAS No. 1603341-18-9) must be handled according to standard laboratory protocols to ensure safety during handling and storage. While it is not classified as a hazardous material under current guidelines, proper precautions should be taken to prevent exposure through inhalation or skin contact. Its stability under various conditions has been thoroughly evaluated, providing guidelines for its safe use in research settings.

The integration of 4,5-Dichloro-2-(trifluoromethyl)quinazoline into drug discovery pipelines aligns with emerging trends in precision medicine. By leveraging structural diversity derived from quinazoline derivatives, researchers can develop targeted therapies tailored to specific genetic or molecular profiles. This approach holds promise for treating complex diseases where traditional monotherapies may fall short.

Future directions in the study of this compound may include exploring its role in neurodegenerative disorders. Quinazoline derivatives have shown promise as kinase inhibitors, which are relevant to pathways implicated in conditions such as Alzheimer's disease. The unique combination of substituents in 4,5-Dichloro-2-(trifluoromethyl)quinazoline may provide insights into novel therapeutic strategies for these challenging conditions.

In conclusion,4,5-Dichloro-2-(trifluoromethyl)quinazoline (CAS No. 1603341-18-9) stands as a testament to the importance of heterocyclic compounds in pharmaceutical innovation. Its structural features offer a rich foundation for designing molecules with tailored biological activities. As research progresses，this compound will continue to contribute to advancements in drug discovery，providing new avenues for treating a wide range of diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)